<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        130-334-10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2010
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        PREDO 25MG TABLETS
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        PREDNISOLONE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        25
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        52.85
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Jazeera Pharmaceutical Industries (JPI)" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 441]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        S01BA04
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Predo belong to a group of medicines called steroids. Their full name is corticosteroids. These corticosteroids occur naturally in the body, and help to maintain health and well-being. Boosting your body with extra corticosteroids (such as Predo) is an effective way to treat various illnesses involving inflammation in the body. Predo reduce this inflammation, which could otherwise go on making your condition worse. You must take this medicine regularly to get maximum benefit from it.<br />Predo is used in a wide range of inflammatory and auto-immune conditions including:</p><ul><li>Allergies, including severe allergic reactions</li><li>Inflammation affecting the:<br />- Lungs, including asthma<br />- Blood vessels and heart<br />- Bowel or kidneys<br />- Muscles and joints, including rheumatoid arthritis<br />- Eye or nervous system</li><li>Skin conditions</li><li>Some infections</li><li>Some cancers, including leukaemia, lymphoma and myeloma</li><li>To prevent organ rejection after a transplant.</li></ul><p>Also:</p><ul><li>To boost steroid levels when the body is not making enough natural steroid on its own</li><li>To treat high calcium levels.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Predo if you:</strong></p><ul><li>Are allergic to prednisolone or any of the other ingredients of this medicine (listed in section 6).</li><li>Have a fungal infection</li><li>Have recently had any &lsquo;live&rsquo; vaccinations.</li></ul><p><strong>Warnings and precautions</strong><br />Talk to your doctor or pharmacist before taking Predo if you have:</p><ul><li>An infection or get an infection while being treated with prednisolone</li><li>Underactive thyroid gland (hypothyroidism)</li><li>Liver disease or kidney failure</li><li>or have had seizures</li><li>Myasthenia gravis (a disease that causes muscle weakness)</li><li>Tuberculosis or have ever been treated for tuberculosis</li><li>Gastric ulcer, duodenal ulcer or inflammatory bowel disease (e.g. ulcerative colitis or diverticulitis)</li><li>Diabetes</li><li>Heart disease, e.g. heart failure or high blood pressure</li><li>Had blood clots in the past (e.g. vein thrombosis) or have blood clots</li><li>Mood swings or psychotic tendencies</li><li>Any drug allergy</li><li>Osteoporosis</li><li>Adrenal tumour (phaeochromocytoma)</li><li>New surgically created blood vessels or intestinal connections</li><li>Scleroderma (also called systemic sclerosis, an autoimmune disease) as daily doses of 15 mg or more can increase the risk of a serious complication called acute kidney crisis. Signs of acute kidney crisis include high blood pressure and decreased urine output. Your doctor may advise you to check your blood pressure and urine levels regularly.</li></ul><p>Contact your doctor if during treatment you:</p><ul><li>Get serious psychological side effects, e.g. depression and suicidal thoughts. These can also occur when you stop taking prednisolone.</li><li>Experience blurred vision or other visual disturbances.</li><li>Are subjected to unusually severe physical or mental strain of any kind (e.g. infection, surgery, trauma) while you are being treated with prednisolone. The dose may need to be increased.</li></ul><p><strong>Increased susceptibility to infections</strong><br />Prednisolone treatment can reduce your resistance to infections, making it easier for you to contract infections during treatment. Chickenpox and measles can become more serious when taking cortisone preparations. Therefore, if you have not previously had these diseases, you should avoid exposing yourself to chickenpox or measles during treatment and talk to a doctor straight away if this should still happen.</p><ul><li>You are more likely to develop infections whilst taking Predo, and existing infections may become worse, especially during periods of stress. Certain infections can be serious if not controlled.</li><li>You may become very ill if you get chickenpox whilst taking Predo. You should avoid contact with people who have chickenpox or shingles whilst taking, and for up to 3 months after you have stopped taking, Predo. Do not stop taking Predo.</li><li>You should avoid contact with people who have measles.</li></ul><p>If you need to be vaccinated during prednisolone treatment, tell your doctor about your treatment before you receive the vaccination.<br />Tumour lysis syndrome can occur when corticosteroids are used in cancer treatment. Tell your doctor if you have cancer and have symptoms of tumour lysis syndrome such as muscle cramps, muscle weakness, confusion, irregular heartbeat, vision loss or disturbances, and shortness of breath.<br />Corticosteroids can cause growth retardation in infants, children and adolescents and therefore longterm use should be avoided. If long-term use is necessary, the growth of infants and children will be closely monitored by the physician.<br /><strong>Other medicines and Predo</strong><br />Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines including medicines obtained without a prescription.<br />It is especially important to tell your doctor if you are taking any of the following medicines:</p><ul><li>Rifampicin, isoniazid (to treat tuberculosis)</li><li>Blood thinners</li><li>Carbamazepine, phenobarbital, phenytoin (antiepilepsy drug)</li><li>Anticholinergics (e.g. medicines for Parkinson&rsquo;s disease or asthma)</li><li>Cholinesterase inhibitors (for myasthenia gravis or Alzheimer&rsquo;s disease)</li><li>Insulin or diabetes drugs in the form of tablets. Cortisone preparations can impair the blood sugar lowering effect of diabetes drugs</li><li>Cobicistat (for HIV infection)</li><li>Oestrogens (e.g. birth control pills)</li><li>Acetylsalicylic acid or other non-steroidal anti-inflammatory agents (NSAIDs) (used to treat pain and inflammation). The risk of peptic ulcer may increase when combined with cortisone preparations</li><li>Thiazides, furosemide, ethacrynic acid (potassium lowering diuretics)</li><li>Xanthines (e.g. theophylline, for treating asthma)</li><li>Beta-2 stimulants (e.g. salbutamol, terbutaline, salmeterol, formoterol, for treating asthma)</li><li>Amphotericin B (antibiotic for fungal infection).</li></ul><p>If you need to be vaccinated, tell your doctor that you are taking Predo.<br /><strong>Pregnancy and breast-feeding</strong><br /><em>Pregnancy</em><br />If you are pregnant, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.<br /><em>Breast-feeding</em><br />If you are breast-feeding, you must tell your doctor before you start the treatment. Your doctor will want to examine your baby during your time of treatment. Small amounts of steroids are present in breast milk.<br /><strong>Driving and using machines</strong><br />Dizziness, visual disturbances and fatigue can occur when using prednisolone. If you experience such symptoms, do not drive or use machines. You are responsible for assessing whether you are in a position to drive a motor vehicle or perform work that requires increased attention. One of the factors that may affect your ability in these respects is the use of drugs because of their effects and/or side effects. A description of these effects and side effects can be found in other sections. Read all the information in this leaflet for guidance. Discuss with your doctor or pharmacist if you are unsure.<br /><strong>Predo contains lactose</strong><br />Predo contains lactose. Each tablet of Predo 5 mg and 25 mg Tablets contains 44 mg or 122.5 mg lactose; respectively. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.<br />Predo should be taken following a meal to reduce the risk of gastric irritation.<br />Different illnesses require different doses of Predo. Depending on your illness your daily dose may be between 5 and 60 mg. In some cases you may be instructed to take it every other day. Your doctor will decide when and how to treat you with Predo.<br />Once your condition starts to get better, your doctor may change your dosage to a lower one. Your doctor may also reduce your dosage before stopping treatment completely. This may depend on your illness, your dosage and how long you have been taking this medicine. In all cases you should be careful to follow any changes.<br /><strong>Treatment of the elderly</strong><br />When steroids are taken by elderly patients some of the unwanted side effects can be more serious especially brittle bone disease, diabetes, high blood pressure, infections and thinning of the skin. Whilst you are taking Predo, if you develop chickenpox, shingles, measles or any infection tell your doctor straight away (refer to section 2 &lsquo;Increased susceptibility to infections&rsquo;).<br /><strong>Mental problems while taking Predo</strong><br />Mental health problems can happen while taking steroids like Predo (see also Section 4 &lsquo;Possible side effects&rsquo;).</p><ul><li>These illnesses can be serious.</li><li>Usually they start within a few days or weeks of starting the medicine.</li><li>They are more likely to happen at high doses.</li><li>Most of these problems go away if the dose is lowered or the medicine is stopped. However, if problems do occur, they might need treatment.</li></ul><p>Talk to a doctor if you (or someone taking this medicine) show any signs of mental problems. This is particularly important if you are depressed, or might be thinking about suicide. In a few cases, mental problems have occurred when doses are being lowered or stopped.<br /><strong>Use in children and adolescents</strong><br />The use of steroids can slow down normal growth of children and adolescents. In order to lessen this effect the tablets are often taken in a single dose every other day.<br /><strong>If you take more Predo than you should</strong><br />If you (or someone else) swallow a lot of tablets at the same time, or you think a child may have swallowed any, contact your nearest hospital casualty department or tell your doctor immediately. Show any leftover medicines or the empty packet to the doctor.<br /><strong>If you forget to take Predo</strong><br />If you forget to take a dose, take one as soon as you remember and then your next dose at the usual time.<br />Never take a double dose to make up for a forgotten dose.<br /><strong>If you stop taking Predo</strong><br />If you stop taking the tablets suddenly you may develop muscle or joint pain, conjunctivitis, fever, weight loss, painful itchy skin lumps or runny nose.<br />In some severe cases a drop in blood pressure and death may occur. If you have been given Predo for more than 3 weeks your doctor will ensure that your dose is gradually reduced so as to avoid any withdrawal symptoms.<br />It is important that you complete the course of treatment as per your doctor&rsquo;s instructions.<br />Talk to your doctor before you stop taking the tablets and follow their advice.<br />If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.<br />Side effects mainly occur with long-term treatment, but also depend on dose size and individual sensitivity.<br />Contact your doctor immediately if the following serious side effects occur:<br /><strong>Not known (frequency cannot be estimated from the available data):</strong></p><ul><li>Severe allergic reaction including angioedema. Symptoms may include: swelling of the face, tongue or throat, difficulty swallowing, hives and difficulty breathing, fever, drop in blood pressure.</li><li>Pheochromocytoma crisis, symptoms may include: anxiety, headache, palpitations, sweating, pale skin.</li><li>Acute renal crisis (in patients already suffering from scleroderma, an autoimmune disease, see section 2 &lsquo;Warnings and precautions&rsquo;). Symptoms may include: high blood pressure and decreased urine output.</li><li>Suicidal ideation (see section 2 &lsquo;Warnings and precautions&rsquo;).</li></ul><p><strong>Other side effects:<br />Common (may affect up to 1 in 10 people):</strong></p><ul><li>Infections, the immunosuppressive effect of prednisolone may also cause infections to flare up again (e.g. tuberculosis)</li><li>Lower concentration of certain hormones, cushings like appearance, growth retardation in children</li><li>Low levels of potassium, build-up of sodium in the body, increased sugar in the blood and urine, osteoporosis</li><li>Swelling due to fluid accumulation, high blood pressure</li><li>Thinner skin, impaired wound healing</li><li>Muscle wasting.</li></ul><p><strong>Uncommon (may affect up to 1 in 100 people):</strong></p><ul><li>Mental disorders (at high doses)</li><li>Cataracts, glaucoma.</li></ul><p><strong>Rare (may affect up to 1 in 1,000 people):</strong></p><ul><li>Depression</li><li>Mania in patients without a history of psychiatric illness</li><li>Benign pressure increase in the skull</li><li>Breakdown of bone tissue, tendon rupture.</li></ul><p><strong>Not known (frequency cannot be estimated from the available data):</strong></p><ul><li>Increased number of white blood cells (leukocytosis)</li><li>Withdrawal syndrome when reducing the dose (see section 3)</li><li>Lowered blood pH, decreased blood potassium, elevated blood fats, impaired sugar tolerance, accumulation of fatty tissue at secluded places in the body, increased appetite (which can lead to weight gain)</li><li>Emotional symptoms (such as elation, emotional instability, drug dependence), mental disorder (such as delusions, hallucinations and schizophrenia), personality change, confusion, anxiety, mood swings, abnormal behaviour, sleep problems, irritability</li><li>Seizures, problems with memory, intellectual disturbance, dizziness, headache, increased amount of fat around the spinal cord</li><li>Acid reduction (central serous chorioretinopathy), protruding eyes, blurred vision</li><li>Heart failure (in susceptible patients)</li><li>Slow heart rate</li><li>Blood clots</li><li>Hiccups</li><li>Gastric ulcer, hole (perforation) in the gut, inflammation of the pancreas, inflammation and ulcers of the oesophagus, swollen abdomen, abdominal pain, diarrhoea, digestive problems, nausea</li><li>Increased hairiness in women, bleeding of the skin, bruising, redness of the skin, sweating, stretch marks (blue-red patches on the chest and abdomen), itching, hives, acne</li><li>Muscle weakness, muscle aches, bone fractures without prior trauma, joint breakdown, joint pain</li><li>Irregular menstrual periods</li><li>Tiredness, feeling ill</li><li>Increased amount of calcium in the urine, elevated liver enzymes (alanine aminotransferase, aspartateaminotransferase), elevated alkaline phosphatase in the blood, elevated levels of blood urea (seen in blood tests), weaker reaction to skin tests.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.<br />Store below 30&deg;C.<br />Store in the original package in order to protect from light.<br />Do not use this medicine after the expiry date which is stated on the package &ldquo;EXP&rdquo;. The expiry date refers to the last day of that month.<br />Do not use this medicine if you notice any visible signs of deterioration.<br />Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to<br />throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is prednisolone.<br />Each tablet of Predo 5 mg and 25 mg Tablets contains 5 mg or 25 mg prednisolone; respectively.<br />The other ingredients are lactose, pregelatinized starch, maize starch, microcrystalline cellulose, povidone and magnesium stearate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Predo 5 mg Tablets are white round-shaped biconvex tablets imprinted with “JPI” on one side and “60” on the other side in clear PVC/PVDC-aluminum blisters.
Predo 25 mg Tablets are white round-shaped biconvex tablets imprinted with “JPI” on one side and “61” on the other side in clear PVC/PVDC-aluminum blisters.
Pack size: 30 Tablets (3 blisters; each blister contains 10 tablets).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorization Holder, Batch releaser and Bulk manufacturer</strong><br />Jazeera Pharmaceutical Industries<br />Al-Kharj Road<br />P.O. BOX 106229<br />Riyadh 11666, Saudi Arabia<br />Tel: + (966-11) 8107023, + (966-11) 2142472<br />Fax: + (966-11) 2078170<br />e-mail: SAPV@hikma.com<br /><strong>Reporting of side effects</strong><br />If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly (see details below). By reporting side effects, you can also help provide more information on the safety of this medicine.</p><ul><li>Saudi Arabia</li></ul><p>The National Pharmacovigilance Centre (NPC)</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p><ul><li>Other GCC States</li></ul><p>Please contact the relevant competent authority.</p><ul><li>United Arab of Emirates</li></ul><p>Pharmacovigilance &amp; Medical Device Section</p><p>P.O. Box: 1853</p><p>Tel: 80011111</p><p>Email: pv@mohap.gov.ae</p><p>Drug Department</p><p>Ministry of Health &amp; Prevention</p><p>Dubai</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in 03/2024; version number Un3.0.

            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">ينتمي بريدو إلى مجموعة من الأدوية تسمى الستيرويدات. الاسم الكامل لهم هو الستيرويدات القشرية. توجد هذه الستيرويدات القشرية بشكل طبيعي في الجسم، وتساعد في الحفاظ على الصحة والعافية. يعد تعزيز جسمك بالستيرويدات القشرية الإضافية (مثل بريدو) طريقة فعالة لعلاج العديد من الأمراض التي تتضمن التهاب في الجسم. يقلل بريدو من هذا الالتهاب، والذي خلاف ذلك يستمر في جعل حالتك أكثر سوءاً. يجب عليك تناول هذا الدواء بانتظام للحصول على أقصى فائدة منه.</p><p dir="RTL">يُستخدَم بريدو في علاج مجموعة واسعة من حالات الالتهاب والمناعة الذاتية بما في ذلك:</p><ul dir="rtl"><li>الحساسية، بما في ذلك ردود الفعل التحسسية الشديدة</li><li>&nbsp;الالتهاب الذي يؤثر على:</li></ul><p dir="RTL" style="margin-right:40px">-&nbsp;&nbsp;&nbsp; الرئتين، بما في ذلك الربو<br />-&nbsp;&nbsp;&nbsp; الأوعية الدموية والقلب<br />-&nbsp;&nbsp;&nbsp; الأمعاء أو الكلى<br />-&nbsp;&nbsp;&nbsp; العضلات والمفاصل، بما في ذلك التهاب المفاصل الروماتويدي<br />-&nbsp;&nbsp;&nbsp; العين أو الجهاز العصبي</p><ul dir="rtl"><li>الحالات الجلدية</li><li>بعض حالات العدوى</li><li>بعض أنواع السرطان، بما في ذلك سرطان الدَّم، سرطان الغدد الليمفاوية والورم النقوي</li><li>لمنع رفض العضو بعد عملية الزراعة.</li></ul><p dir="RTL">وكذلك:</p><ul dir="rtl"><li>لتعزيز مستويات الستيرويد عندما لا ينتج الجسم ما يكفي من الستيرويد الطبيعي بمفرده</li><li>لعلاج مستويات الكالسيوم المرتفعة.</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تتناول بريدو إذا:</strong></p><ul dir="rtl"><li>كنت تعاني من حساسية لبريدنيزولون أو لأي من المواد الأخرى المستخدمة في تركيبة هذا الدواء (المذكورة في القسم 6).</li><li>كان لديك عدوى فطرية</li><li>كنت قد تلقيت مؤخراً أي تطعيمات &rsquo;حية&lsquo;.</li></ul><p dir="RTL"><strong>الاحتياطات والتحذيرات</strong><br />تحدث مع طبيبك أو الصيدلي قبل تناول بريدو إذا كان لديك:</p><ul dir="rtl"><li>عدوى أو أصبت بعدوى أثناء علاجك باستخدام بريدنيزولون</li><li>قصور نشاط الغدة الدرقية (قصور الدرقية)</li><li>مرض في الكبد أو فشل كلوي</li><li>أو إذا قد كنت تعرضت فيما مضى للإصابة بنوبات</li><li>الوهن العضلي الوبيل (مرض يسبب ضعف العضلات)</li><li>السُّل أو إذا كنت قد تلقيت علاج السُّل في أي وقت مضى</li><li>قرحة المعدة، قرحة الاثني عشر أو مرض الأمعاء الالتهابي (مثل التهاب القولون التقرحي أو التهاب الرَّتج)</li><li>السكري</li><li>مرض في القلب، على سبيل المثال فشل القلب أو ارتفاع ضغط الدم</li><li>إذا كنت قد عانيت من جلطات دموية في الماضي (على سبيل المثال التخثر في الوريد) أو تعاني من جلطات دموية</li><li>تقلبات الحالة المزاجية أو ميول ذهانية</li><li>أي حساسية دوائية</li><li>هشاشة العظام</li><li>ورم الغدة الكظرية (ورم القواتم)</li><li>أوعية دموية أو وصلات معوية جديدة تم إنشاؤها جراحياً</li><li>تصلب الجلد (يعرف أيضاً باسم التصلب المجموعي، وهو أحد أمراض المناعة الذاتية) حيث يمكن أن تؤدي الجرعات اليومية من 15 ملغم أو أكثر إلى زيادة خطر الإصابة بمضاعفات خطيرة تُعرف باسم نوبات الكلى الحادة. علامات نوبات الكلى الحادة تشمل ارتفاع ضغط الدم وانخفاض النتاج البولي. قد ينصحك طبيبك بفحص ضغط الدم ومستويات البول لديك بانتظام.</li></ul><p dir="RTL">اتصل بطبيبك إذا حدث لديك ما يلي أثناء العلاج:</p><ul dir="rtl"><li>إذا عانيت من آثار جانبية نفسية خطيرة، مثل الاكتئاب والأفكار الانتحارية. يمكن أن تحدث هذه أيضاً عند التوقف عن تناول بريدنيزولون.</li><li>إذا حدث لديك عدم وضوح في الرؤية أو غيرها من اضطرابات الرؤية.</li><li>إذا تعرضت لإجهاد بدني أو ذهني شديد بشكل غير عادي من أي نوع (على سبيل المثال عدوى، جراحة، إصابة) أثناء علاجك باستخدام بريدنيزولون. قد تكون هناك حاجة لزيادة الجرعة.</li></ul><p dir="RTL"><strong>زيادة القابلية للإصابة بالعدوى</strong><br />يمكن أن يقلل العلاج باستخدام بريدنيزولون من مقاومتك للعدوى، مما يسهل الإصابة بالعدوى أثناء العلاج. يمكن أن يصبح جدري الماء والحصبة أكثر خطورة عند تناول مستحضرات الكورتيزون. لذا، إذا لم يسبق لك الإصابة بهذه الأمراض، يجب عليك تجنب تعريض نفسك لجدري الماء أو الحصبة أثناء العلاج وتحدث إلى الطبيب على الفور إذا كنت لا تزال تتعرض لذلك.</p><ul dir="rtl"><li>أنت أكثر عرضة للإصابة بالعدوى أثناء تناول بريدو، وقد تصبح العدوى الحالية أسوأ، خاصةً خلال فترات الإجهاد. يمكن أن تكون بعض أنواع العدوى خطيرة إذا لم يتم السيطرة عليها.</li><li>قد تصاب بمرض شديد إذا أصبت بجدري الماء أثناء تناول بريدو. يجب عليك تجنب الاتصال بالأشخاص المصابين بجدري الماء أو الهربس النطاقي أثناء تناول بريدو، ولمدة تصل إلى 3 أشهر بعد أن تتوقف عن تناول بريدو. لا تتوقف عن تناول بريدو.</li><li>يجب عليك تجنب الاتصال بالأشخاص المصابين بالحصبة.</li></ul><p dir="RTL">إذا كنت بحاجة إلى التطعيم أثناء العلاج ببريدنيزولون، أخبر طبيبك عن علاجك قبل تلقي التطعيم.</p><p dir="RTL">يمكن أن تحدث متلازمة تحلل الورم عند استخدام الستيرويدات القشرية في علاج السرطان. أخبر طبيبك إذا كنت مصاباً بالسرطان ولديك أعراض متلازمة تحلل الورم مثل التشنجات العضلية، ضعف العضلات، الارتباك، عدم انتظام ضربات القلب، فقدان الرؤية أو اضطرابات الرؤية، وضيق في التنفس.</p><p dir="RTL">يمكن أن تسبب الستيرويدات القشرية تأخر النمو لدى الرضع، الأطفال والمراهقين ولذلك ينبغي تجنب الاستخدام على المدى الطويل. إذا كان الاستخدام طويل الأمد ضرورياً، فسيتم مراقبة نمو الرضع والأطفال عن كثب من قِبل الطبيب.</p><p dir="RTL"><strong>الأدوية الأخرى وبريدو</strong><br />أخبر طبيبك أو الصيدلي إذا كنت تتناول، تناولت مؤخراً، أو قد تتناول أية أدوية أخرى، بما في ذلك الأدوية التي يتم الحصول عليها دون وصفة طبية.</p><p dir="RTL">من المهم بشكل خاص أن تخبر طبيبك إذا كنت تتناول أي من الأدوية التالية:</p><ul dir="rtl"><li>ريفامبيسين، إيزونيازيد (لعلاج السُّل)</li><li>مميعات الدم</li><li>كربامازيبين، فينوباربيتال أو فنيتوين (أدوية مضادة للصرع)</li><li>مضادات الكُولينِيَّات (على سبيل المثال الأدوية التي تُستخدَم لعلاج مرض باركنسون أو الربو)</li><li>مثبطات الكولينستيراز (لعلاج الوهن العضلي الوبيل أو مرض الزهايمر)</li><li>الإنسولين أو أدوية السكري على شكل أقراص. مستحضرات الكورتيزون يمكن أن تضعف تأثير أدوية السكري في خفض نسبة السكر في الدم</li><li>كوبيسيستات (لعلاج عدوى فيروس نقص المناعة البشرية)</li><li>الاستروجينات (على سبيل المثال حبوب منع الحمل)</li><li>حمض الأسيتيل ساليساليك أو غيره من مضادات الالتهاب غير الستيرويدية (التي تُستخدَم لعلاج الألم والالتهاب). قد يزداد خطر الإصابة بالقرحة الهضمية عند استخدامهم مع مستحضرات الكورتيزون</li><li>أدوية الثيازيد، فيروسيمايد، حمض الإيثاكرِينِيك (مدرات البول التي تعمل على خفض البوتاسيوم)</li><li>الزانثين (على سبيل المثال الثيوفيلين، لعلاج الربو)</li><li>منشطات بيتا-2 (على سبيل المثال سالبوتامول، تيربوتالين، سالميترول، فورموتِرول، لعلاج الربو)</li><li>أمفوتيريسين ب (مضاد حيوي للعدوى الفطرية).</li></ul><p dir="RTL">إذا كنت بحاجة إلى التطعيم، أخبر طبيبك بأنك تتناول بريدو.</p><p dir="RTL"><strong>الحمل والرضاعة</strong><br /><em>الحمل</em><br />اطلبي النصيحة من طبيبك أو الصيدلي قبل تناول هذا الدواء إذا كنت حاملاً، تعتقدين بأنك حامل أو تخططين لذلك.</p><p dir="RTL"><em>الرضاعة</em><br />إذا كنت مرضعاً، يجب أن تخبري طبيبك قبل بدء العلاج. سيحتاج طبيبك إلى فحص طفلك أثناء تلقيك للعلاج. توجد كميات صغيرة من الستيرويدات في حليب الثدي.<strong>&nbsp;</strong></p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong><br />يمكن أن يحدث دوخة، اضطرابات في الرؤية وتعب أثناء استخدام بريدنيزولون. إذا واجهت مثل هذه الأعراض، فلا تقود أو تستخدم الآلات. أنت مسؤول عن تقييم ما إذا كنت في وضع يسمح لك بقيادة سيارة أو أداء عمل يتطلب تركيزاً كبيراً. أحد العوامل التي قد تؤثر على قدرتك في هذه النواحي هو استخدام الأدوية بسبب تأثيرها و/أو آثارها الجانبية. يمكن العثور على وصف لهذه التأثيرات والآثار الجانبية في أقسام أخرى. اقرأ جميع المعلومات الواردة في هذه النشرة للحصول على إرشادات. ناقش الأمر مع طبيبك أو الصيدلي إذا لم تكن متأكداً.</p><p dir="RTL"><strong>يحتوي بريدو على اللاكتوز</strong><br />يحتوي بريدو على اللاكتوز. يحتوي كل قرص من بريدو 5 ملغم و25 ملغم أقراص على 44 ملغم أو 122.5 ملغم لاكتوز؛ على التوالي. إذا أخبرك طبيبك بأن لديك عدم تحمل لبعض السكريات، فاتصل بطبيبك قبل تناول هذا المستحضر الدوائي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">قم دائماً بتناول دوائك كما أخبرك طبيبك أو الصيدلي تماماً. تحقق من طبيبك أو الصيدلي إذا لم تكن متأكداً.</p><p dir="RTL">يجب تناول بريدو بعد تناول الوجبة لخفض خطر الإصابة بتهيج المعدة.</p><p dir="RTL">تتطلب الأمراض المختلفة جرعات مختلفة من بريدو. وحسب مرضك، قد تتراوح جرعتك اليومية بين 5 و60 ملغم. في بعض الحالات، قد يُطلب منك تناوله كل يومين. سيقرر طبيبك متى وكيف يتم علاجك باستخدام بريدو.</p><p dir="RTL">بمجرد أن تبدأ حالتك في التحسن، قد يغير طبيبك جرعتك إلى جرعة أقل. قد يخفض طبيبك أيضاً من جرعتك قبل إيقاف العلاج تماماً. قد يعتمد هذا على مرضك، جرعتك ومدة تناولك لهذا الدواء. في جميع الحالات، يجب عليك الحرص على متابعة أي تغييرات.</p><p dir="RTL"><strong>علاج كبار السن</strong><br />عندما يتم تناول الستيرويدات من قبل كبار السن من المرضى، يمكن أن تكون بعض الآثار الجانبية غير المرغوب فيها أكثر خطورة وبخاصة داء هشاشة العظام، السكري، ارتفاع ضغط الدم، العدوى وترقق الجلد.</p><p dir="RTL">أثناء تناولك بريدو، إذا أصبت بجدري الماء، الهربس النطاقي، الحصبة أو أي عدوى أخبر طبيبك على الفور (راجع القسم 2 &rsquo;زيادة القابلية للإصابة بالعدوى&lsquo;).</p><p dir="RTL"><strong>المشاكل العقلية أثناء تناول بريدو</strong><br />يمكن أن تحدث مشاكل في الصحة العقلية أثناء تناول الستيرويدات مثل بريدو (انظر أيضاً القسم 4 &rsquo;الآثار الجانبية المحتملة&lsquo;).</p><ul dir="rtl"><li>يمكن أن تكون هذه الأمراض خطيرة.</li><li>وتبدأ عادةً في غضون أيام أو أسابيع قليلة من بدء الدواء.</li><li>يكون من المرجح أن تحدث مع الجرعات العالية.</li><li>تختفي معظم هذه المشاكل إذا تم خفض الجرعة أو تم التوقف عن تناول الدواء. ولكن، إذا حدثت مشاكل، فقد تحتاج إلى علاج.</li></ul><p dir="RTL">تحدث إلى الطبيب إذا ظهر لديك (أو لدى أي شخص يتناول هذا الدواء) أي علامات لمشاكل عقلية. هذا الأمر مهم بشكل خاص إذا كنت مكتئباً، أو قد تفكر في الانتحار. في حالات قليلة، حدثت مشكلات عقلية عند خفض الجرعات أو إيقافها.</p><p dir="RTL"><strong>الاستخدام لدى الأطفال والمراهقين</strong><br />يمكن أن يؤدي استخدام الستيرويدات إلى إبطاء النمو الطبيعي لدى لأطفال والمراهقين. لتقليل هذا التأثير غالباً ما يتم تناول الأقراص في جرعة واحدة كل يوم بعد يوم.</p><p dir="RTL"><strong>إذا تناولت بريدو أكثر من اللازم</strong><br />إذا ابتلعت (أو أي شخص آخر) الكثير من الأقراص في نفس الوقت، أو كنت تعتقد أن الطفل قد ابتلع أياً منها، فاتصل بقسم الإصابات في أقرب مستشفى لك أو أخبر طبيبك على الفور. أظهر أي أدوية متبقية أو العبوة الفارغة للطبيب.</p><p dir="RTL"><strong>إذا نسيت تناول بريدو</strong><br />إذا نسيت تناول الجرعة، فتناولها بمجرد تذكرها ثم بعد ذلك تناول الجرعة التالية في موعدها المعتاد.</p><p dir="RTL">لا تقم مطلقاً بتناول جرعة مضاعفة لتعويض الجرعة المنسية.<strong>&nbsp;</strong></p><p dir="RTL"><strong>إذا توقفت عن تناول بريدو</strong><br />إذا توقفت عن تناول الأقراص فجأة، فقد تصاب بألم في العضلات أو المفاصل، التهاب الملتحمة، الحمى، فقد الوزن، تكتلات مؤلمة مصحوبة بحكة في الجلد أو سيلان الأنف.</p><p dir="RTL">في بعض الحالات الشديدة قد يحدث انخفاض في ضغط الدم والوفاة. إذا تم إعطاؤك بريدو لأكثر من 3 أسابيع، فسيتحقق طبيبك من خفض جرعتك تدريجياً لتجنب أي أعراض انسحابية.</p><p dir="RTL">من المهم إكمال دورة العلاج وفقاً لإرشادات الطبيب.</p><p dir="RTL">تحدث مع طبيبك قبل التوقف عن تناول الأقراص واتبع نصائحه.</p><p dir="RTL">إذا كان لديك أي أسئلة إضافية حول استخدام هذا الدواء، اسأل الطبيب أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، قد يسبب هذا الدواء آثاراً جانبيةً، إلا أنه ليس بالضرورة أن تحدث لدى جميع مستخدمي هذا الدواء.</p><p dir="RTL">تحدث الآثار الجانبية بشكل أساسي مع العلاج طويل الأمد، ولكنها تعتمد أيضاً على حجم الجرعة والحساسية الفردية.</p><p dir="RTL">اتصل بالطبيب على الفور في حالة حدوث الآثار الجانبية الخطيرة التالية:</p><p dir="RTL"><strong>غير معروف (لا يمكن تقدير التكرار من البيانات المتاحة):</strong></p><ul dir="rtl"><li>رد فعل تحسسي شديد بما في ذلك الوذمة الوعائية. قد تشمل الأعراض: تورم الوجه، اللسان أو الحلق، صعوبة في البلع، شرى وصعوبة في التنفس، حمى، انخفاض ضغط الدم.</li><li>نوبة ورم القواتم، قد تشمل الأعراض: القلق، الصداع، الخفقان، التعرق، الجلد الشاحب.</li><li>نوبة كلوية حادة (في المرضى الذين يعانون بالفعل من تصلب الجلد، أحد أمراض المناعة الذاتية، انظر القسم 2 &rsquo;الاحتياطات والتحذيرات&lsquo;). قد تشمل الأعراض: ارتفاع ضغط الدم وانخفاض النتاج البولي.</li><li>تفكير انتحاري (انظر القسم 2 &rsquo;الاحتياطات والتحذيرات&lsquo;).</li></ul><p dir="RTL"><strong>آثار جانبية أخرى:<br />شائعة</strong> <strong>(قد تؤثر فيما يصل إلى شخص من بين كل 10 أشخاص):</strong></p><ul dir="rtl"><li>العدوى، قد يؤدي تأثير بريدنيزولون المثبط للمناعة أيضاً إلى تفاقم حالات العدوى مرة أخرى (على سبيل المثال، السُّل)</li><li>انخفاض تركيز هرمونات معينة، مظهر مشابه لداء كوشينغ، تأخر النمو لدى الأطفال</li><li>انخفاض مستويات البوتاسيوم، تراكم الصوديوم في الجسم، زيادة السكر في الدم والبول، هشاشة العظام</li><li>تورم بسبب تراكم السوائل، ارتفاع ضغط الدم</li><li>ترقق الجلد، &rlm;‫ضعف التئام الجروح</li><li>الهزال العضلي.</li></ul><p dir="RTL"><strong>غير شائعة (قد تؤثر فيما يصل إلى شخص من بين كل 100 شخص):</strong></p><ul dir="rtl"><li>اضطرابات عقلية (في حالة الجرعات العالية)</li><li>إعتام عدسة العين، الزَرَق.</li></ul><p dir="RTL"><strong>نادرة (قد تؤثر فيما يصل إلى شخص من بين كل 1000 شخص):</strong></p><ul dir="rtl"><li>الاكتئاب</li><li>الهوس لدى المرضى الذين ليس لديهم تاريخ من الأمراض النفسية</li><li>زيادة الضغط الحميد في الجمجمة</li><li>اختلال أنسجة العظام، تمزق الوتر.</li></ul><p dir="RTL"><strong>غير معروف (لا يمكن تقدير التكرار من البيانات المتاحة):</strong></p><ul dir="rtl"><li>زيادة عدد خلايا الدم البيضاء (كثرةُ الكريات البِيض)</li><li>متلازمة الانسحاب عند خفض الجرعة (انظر القسم 3)</li><li>انخفاض درجة حموضة الدم، انخفاض بوتاسيوم الدم، ارتفاع الدهون في الدم، خلل في القدرة على تحمل السكر، تراكم الأنسجة الدهنية في أماكن منعزلة في الجسم، زيادة الشهية (والتي يمكن أن تؤدي إلى زيادة الوزن)</li><li>أعراض انفعالية (مثل الابتهاج، عدم الاستقرار العاطفي، الاعتماد على الأدوية)، اضطرابات عقلية (مثل الأوهام، الهَلْوَسات والفُصام)، تغير الشخصية، الارتباك، القلق، تقلبات الحالة المزاجية، سلوك غير طبيعي، مشاكل في النوم، التهيُجيَّة</li><li>نوبات، مشاكل في الذاكرة، اضطرابات ذهنية، الدوخة، الصداع، زيادة كمية الدهون حول الحبل الشوكي</li><li>انخفاض الأحماض (اعْتِلاَلُ المَشيمِيَّةِ والشَّبَكِيَّة المَرْكَزِيُّ المَصْلِيّ)، جحوظ العينين، عدم وضوح الرؤية</li><li>فشل القلب (في المرضى المعرضين للإصابة)</li><li>انخفاض معدل ضربات القلب</li><li>الجلطات الدموية</li><li>الحازُوقَة</li><li>القرحة المَعِدِيَّة، فتحة (انثقاب) في الأمعاء، التهاب البنكرياس، التهاب وقرح المريء، تورم البطن، ألم في البطن، إسهال، مشاكل في الهضم، الغثيان</li><li>زيادة الشعر لدى النساء، نزيف الجلد، الكدمات، احمرار الجلد، التعرق، علامات التمدد (بقع زرقاء-حمراء على الصدر والبطن)، الحكة، الشرى، حَبُّ الشّبَاب</li><li>ضعف العضلات، آلام العضلات، كسور العظام من دون إصابة سابقة، تفكك المفاصل، وجع المفاصل</li><li>دورات شهرية غير منتظمة</li><li>الإرهاق، الشعور بالمرض</li><li>زيادة كمية الكالسيوم في البول، ارتفاع إنزيمات الكبد (ناقلة أمين الألانين، ناقلة أمين الأَسبارتات)، ارتفاع الفسفاتاز القلوي في الدم، ارتفاع مستويات يوريا الدم (التي تظهر في اختبارات الدم)، رد فعل أضعف لاختبارات الجلد.</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احفظ هذا الدواء بعيداً عن مرأى ومتناول الأطفال.</p><p dir="RTL">يحفظ عند درجة حرارة أقل من 30&deg; مئوية.</p><p dir="RTL">يحفظ داخل العبوة الأصلية للحماية من الضوء.</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على العبوة الخارجية بعد &quot;EXP&quot;. يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">لا تستخدم هذا الدواء إذا لاحظت أي علامات تلف واضحة عليه.</p><p dir="RTL">لا تتخلص من أي أدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. هذه الإجراءات ستساعد في الحفاظ على سلامة البيئة.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعالة هي بريدنيزولون.</p><p dir="RTL">يحتوي كل قرص من بريدو 5 ملغم و25 ملغم أقراص على 5 ملغم أو 25 ملغم بريدنيزولون؛ على التوالي.</p><p dir="RTL">المواد الأخرى المستخدمة في التركيبة التصنيعية هي لاكتوز، النشا المعدّل، نشا الذرة، سيلليلوز بلوري مكروي، بوڤیدون وستيرات المغنيسيوم.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">بريدو 5 ملغم أقراص هي أقراص لونها أبيض دائرية الشكل محدبة الوجهين مطبوع عليها &quot;JPI&quot; على جهة واحدة و&quot;60&quot; على الجهة الأخرى في أشرطة شفافة من كلوريد متعدد الڤينيل/ثنائي كلوريد متعدد الڤينيليدين-الألومنيوم.</p><p dir="RTL">بريدو 25 ملغم أقراص هي أقراص لونها أبيض دائرية الشكل محدبة الوجهين مطبوع عليها &quot;JPI&quot; على جهة واحدة و&quot;61&quot; على الجهة الأخرى في أشرطة شفافة من كلوريد متعدد الڤينيل/ثنائي كلوريد متعدد الڤينيليدين-الألومنيوم.</p><p dir="RTL">حجم العبوة: 30 قرص (3 أشرطة؛ كل شريط يحتوي على 10 أقراص).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مالك رخصة التسويق</strong><strong>، محرر التشغيلة</strong><strong> والشركة المصنعة للمستحضر النهائي</strong></p><p dir="RTL">شركة الجزيرة للصناعات الدوائية</p><p dir="RTL">طريق الخرج</p><p dir="RTL">صندوق بريد 106229</p><p dir="RTL">الرياض 11666، المملكة العربية السعودية</p><p dir="RTL">هاتف: 8107023 (11-966) +، 2142472 (11-966) +</p><p dir="RTL">فاكس: 2078170 (11-966) +</p><p dir="RTL">البريد الإلكتروني: SAPV@hikma.com</p><p dir="RTL"><strong>للإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL">تحدث إلى الطبيب، الصيدلي، أو الممرض إذا عانيت من أية آثار جانبية. وذلك يشمل أي آثار جانبية لم يتم ذكرها في هذه النشرة. كما أنه يمكنك الإبلاغ عن هذه الآثار مباشرةً (انظر التفاصيل المذكورة أدناه). من خلال الإبلاغ عن الآثار الجانبية، يمكنك المساعدة بتوفير معلومات مهمة عن سلامة الدواء.</p><ul dir="rtl"><li>المملكة العربية السعودية</li></ul><p dir="RTL">المركز الوطني للتيقظ الدوائي</p><p dir="RTL">مركز الاتصال الموحد: 19999</p><p dir="RTL">البريد الإلكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">الموقع الإلكتروني:&nbsp; https://ade.sfda.gov.sa</p><ul dir="rtl"><li>دول الخليج العربي الأخرى</li></ul><p dir="RTL">الرجاء الاتصال بالجهات الوطنية في كل دولة. &nbsp;</p><ul dir="rtl"><li>الإمارات العربية المتحدة</li></ul><p dir="RTL">قسم اليقظة الدوائية والجهاز الطبي</p><p dir="RTL">صندوق بريد: 1853</p><p dir="RTL">هاتف: 80011111</p><p dir="RTL">البريد الإلكتروني: pv@mohap.gov.ae</p><p dir="RTL">إدارة الدواء</p><p dir="RTL">وزارة الصحة ووقاية المجتمع</p><p dir="RTL">دبي</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة هذه النشرة بتاريخ 03/2024؛ رقم النسخة Un3.0.


        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Predo 25 mg Tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each tablet contains 25 mg prednisolone.

Excipient with known effect: Lactose.

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tablets.

White round-shaped biconvex tablets imprinted with “JPI” on one side and “61” on the other side.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Allergy and anaphylaxis</strong>: bronchial asthma, drug hypersensitivity reactions, serum sickness, angioneurotic oedema, anaphylaxis, incapacitating allergies unresponsive to conventional treatment.</p><p><strong>Arteritis/collagenosis</strong>: giant cell arteritis/polymyalgia rheumatica, mixed connective tissue disease, polyarteritis nodosa, polymyositis.</p><p><strong>Blood disorders</strong>: haemolytic anaemia (auto-immune), leukaemia (acute and chronic lymphocytic), lymphoma, multiple myeloma, idiopathic thrombocytopenic purpura.</p><p><strong>Cardiovascular disorders</strong>: post-myocardial infarction syndrome, rheumatic fever with severe carditis.</p><p><strong>Endocrine disorders</strong>: primary and secondary adrenal insufficiency, congenital adrenal hyperplasia.</p><p><strong>Gastro-intestinal disorders</strong>: regional ileitis (Crohn&#39;s disease), ulcerative colitis, persistent coeliac syndrome (coeliac disease unresponsive to gluten withdrawal), auto-immune chronic active hepatitis, multisystem disease affecting liver, biliary peritonitis.</p><p><strong>Hypercalcaemia</strong>: sarcoidosis, vitamin D excess.</p><p><strong>Infections (with appropriate chemotherapy)</strong>: helminthic infestations, Herxheimer reaction, infectious mononucleosis, miliary tuberculosis, mumps orchitis (adult), tuberculous meningitis, rickettsial disease.</p><p><strong>Muscular disorders</strong>: polymyositis, dermatomyositis.</p><p><strong>Neurological disorders</strong>: infantile spasms, Shy-Drager syndrome, sub-acute demyelinating polyneuropathy.</p><p><strong>Ocular disease</strong>: scleritis, posterior uveitis, retinal vasculitis, pseudo-tumours of the orbit, giant cell arteritis, malignant ophthalmic Graves disease.</p><p><strong>Renal disorders</strong>: lupus nephritis, acute interstitial nephritis, minimal change glomerulonephritis, nephrotic syndrome.</p><p><strong>Respiratory disease</strong>: allergic pneumonitis, asthma, occupational asthma, pulmonary aspergillosis, pulmonary fibrosis, pulmonary alveolitis, aspiration of foreign body, aspiration of stomach contents, pulmonary sarcoid, drug induced lung disease, adult respiratory distress syndrome, spasmodic croup, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy.</p><p><strong>Rheumatic disorders</strong>: rheumatoid arthritis, polymyalgia rheumatica, juvenile chronic arthritis, psoriatic arthritis, systemic lupus erythematosus, dermatomyositis, mixed connective tissue disease.</p><p><strong>Skin disorders</strong>: pemphigus vulgaris, exfoliative dermatitis, bullous pemphigoid, systemic lupus erythematosus, pyoderma gangrenosum.</p><p><strong>Miscellaneous</strong>: sarcoidosis, hyperpyrexia, Beh&ccedil;ets disease, immunosuppression in organ transplantation.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Posology</strong><br /><u>Adults and the elderly</u><br />The lowest effective dose should be used for the minimum period.</p><p><u>Children</u><br />Predo should only be used when specifically indicated, at the lowest dose possible and for the shortest possible time.</p><p>The initial dosage of prednisolone may vary from 5 mg to 60 mg daily depending on the disorder being treated. Divided daily dosage may be used. Administration as a once daily dose in the morning or on alternate days can reduce the risk of adrenocortical suppression (see section 4.4 Special warnings and precautions for use). In some patients this may not be possible e.g. patients with rheumatoid arthritis with pronounced morning stiffness where an evening dose may need to be given.</p><p>The following therapeutic guidelines should be kept in mind for all therapy with</p><p>corticosteroids:</p><p>The lowest dose to produce an acceptable result should be given. Initial dosage should be adjusted until the desired clinical response has been achieved. The dose should be gradually reduced until the lowest dose which will maintain an adequate clinical response is reached. As a guide, the daily dose should be reduced by 2.5 &ndash; 5 mg every second to fifth day (more rapidly at the higher initial dose levels) until the lowest possible maintenance dose is reached. Preferably this should not exceed 10 mg per day. Use of the lowest effective dose will tend to minimise side-effects. The incidence of side-effects increases with dose and duration of treatment (see section 4.4 &#39;Special warnings and precautions for use&#39;).</p><p>Particular care should be exercised in patients who have received higher than 7.5 mg prednisolone daily or equivalent for more than 3 weeks, owing to a greater risk of suppression of the hypothalamic-pituitary-adrenal (HPA) axis in these patients. The speed with which dose can be reduced is also dependent on risk of relapse of the disease being treated. After prolonged treatment, tapering of dose below 7.5 mg (regarded as &ldquo;equivalent&rdquo; to physiological levels of glucocorticoids) should be conducted particularly cautiously.</p><p>More rapid withdrawal of systemic corticosteroid treatment that has been given for less than 3 weeks is appropriate if it is considered that the disease is unlikely to relapse. Withdrawal of doses of up to 40 mg daily of prednisolone, or equivalent that have been administered for less than 3 weeks is unlikely to lead to clinically relevant HPA-axis suppression, in the majority of patients. In the following patient groups, gradual withdrawal of systemic corticosteroid therapy should be considered even after courses lasting 3 weeks or less:</p><ul><li>Patients who have had repeated courses of systemic corticosteroids, particularly if taken for greater than 3 weeks.</li><li>When a short course has been prescribed within one year of cessation of long-term therapy (months or years).</li><li>Patients who may have reasons for adrenocortical insufficiency other than exogenous corticosteroid therapy.</li><li>Patients receiving doses of systemic corticosteroid greater than 40 mg daily of prednisolone (or equivalent).</li><li>Patients repeatedly taking doses in the evening.</li></ul><p>(See section 4.4 &#39;Special warnings and precautions for use&#39; and section 4.8 &#39;Undesirable effects&#39;).</p><p>During prolonged therapy, dosage may need to be temporarily increased during periods of stress or during exacerbations of the disease (see section 4.4 &#39;Special warnings and precautions for use&#39;).</p><p>If there is lack of a satisfactory clinical response to Predo, the drug should be gradually discontinued and the patient transferred to alternative therapy.</p><p><u>Intermittent dosage regimen</u><br />A single dose of Predo in the morning on alternate days or at longer intervals is acceptable therapy for some patients. When this regimen is practical, the degree of pituitary-adrenal suppression can be minimised.</p><p><u>Specific dosage guidelines</u><br />The following recommendations for some corticosteroid-responsive disorders are for guidance only. Acute or severe disease may require initial high dose therapy with reduction to the lowest effective maintenance dose as soon as possible. Dosage reductions should not exceed 5-7.5 mg daily during chronic treatment.</p><p><em>Allergic and skin disorders</em><br />Initial doses of 5-15 mg daily are commonly adequate.</p><p><em>Collagenosis</em><br />Initial doses of 20-30 mg daily are frequently effective. Those with more severe symptoms may require higher doses.</p><p><em>Rheumatoid arthritis</em><br />The usual initial dose is 10-15 mg daily. The lowest daily maintenance dose compatible with tolerable symptomatic relief is recommended.</p><p><em>Blood disorders and lymphoma</em><br />An initial daily dose of 15-60 mg is often necessary with reduction after an adequate clinical or haematological response. Higher doses may be necessary to induce remission in acute leukaemia.</p><p><u>Special populations</u><br /><em>Use in elderly</em><br />Treatment of elderly patients, particularly if long-term, should be undertaken with caution bearing in mind the more serious consequences of the common side-effects of corticosteroids in old age (see also &#39;Special warnings and precautions for use&#39;).</p><p><em>Use in children</em><br />Although appropriate fractions of the adult dose may be used, dosage will usually be determined by clinical response as in adults (see also section 4.4 &#39;Special warnings and precautions for use&#39; and section 4.8 &#39;Undesirable effects&#39;). Alternate day dosage is preferable where possible.</p><p><strong>Method of administration</strong><br />Predo should be taken following a meal to reduce the risk of gastric irritation.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Systemic yeast infection.
Administration of live vaccines is contraindicated in patients receiving corticosteroids in immunosuppressive doses.
In those conditions when treatment with prednisolone can save lives, none of the contraindications generally apply.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Since the complications of glucocorticoid therapy are dependent on the dose and duration of treatment, a risk / benefit assessment must be made in each case regarding dose and duration of treatment, as well as whether daily or intermittent treatment should be used.</p><p>The lowest possible corticosteroid dose needed to control the disease being treated should be used. When dose reduction is possible, it should be gradual.</p><p><strong>Immunosuppressive effects / increased susceptibility to infection</strong><br />Glucocorticoids, including prednisolone, may cause increased susceptibility to infection, masking symptoms of infection, and new infections may occur during treatment.</p><p>Infections caused by viruses, bacteria, fungi, protozoa or intestinal worms may be associated with the use of corticosteroids alone or corticosteroids in combination with other immunosuppressive agents that affect cellular immunity, humoral immunity or the function of neutrophils. The infections can be mild, but also difficult and in some cases fatal. The risk of infectious complications increases with increasing dose.</p><p>Glucocorticoids should not be given during infections without concomitant causal treatment.</p><p>Chickenpox and measles can be more serious or even fatal in non-immunised children and adults treated with corticosteroids. Children, or adults who have not had these diseases, and who take immunosuppressive doses of corticosteroids, should be advised to avoid exposure to chickenpox and measles, and to seek care when exposed.</p><p>The use of prednisolone in active tuberculosis must be limited to those cases of fulminant or disseminated tuberculosis where the corticosteroid is used to treat the disease in combination with appropriate tuberculosis therapy. If corticosteroids are indicated in patients with latent tuberculosis or tuberculin reactivity, close monitoring is necessary as the disease can be reactivated. In long-term corticosteroid therapy, these patients should receive tuberculosis prophylaxis.</p><p>High dose corticosteroids may interfere with active immunisation.</p><p>Vaccination with live vaccine should be done under close supervision and not in patients on long-term treatment with corticosteroids in immunosuppressive doses.</p><p><strong>Immune system</strong><br />Since rare cases of skin reactions and anaphylactic / anaphylactoid reactions have occurred in patients treated with corticosteroids, appropriate precautions should be taken prior to administration, especially if the patient has previously had an allergic reaction to any drug.</p><p><strong>Endocrine system</strong><br />Long-term treatment with pharmacological doses of corticosteroid may lead to secondary adrenal insufficiency. The risk can be reduced by giving the treatment every other day (see section 4.2).</p><p>Patients who receive corticosteroid maintenance therapy and are exposed to unusual stresses (e.g. infection, surgery or trauma) need higher corticosteroid doses before, during and after the stressful situation.</p><p>Abrupt discontinuation of treatment may lead to acute adrenal insufficiency which may be fatal. The risk of secondary adrenal insufficiency can be reduced by gradually decreasing the dose. This type of relative insufficiency may persist for months after the end of treatment, so hormone replacement therapy should be reintroduced in stressful situations occurring during this time period. Since the secretion of mineral corticoids may be impaired, salts and / or mineral corticoids should be administered simultaneously.</p><p>A &quot;steroid withdrawal syndrome&quot;, apparently without associated with adrenal insufficiency, may also occur following abrupt withdrawal of glucocorticoids. This syndrome causes symptoms such as anorexia, nausea, vomiting, lethargy, headache, fever, joint pain, desquamation, myalgia, weight loss and / or hypotension. These effects are believed to be due to the sudden change in glucocorticosteroid concentration rather than to low corticosteroid levels.</p><p>Patients with hypothyroidism or liver cirrhosis will have an enhanced effect of corticosteroids.</p><p>Pheochromocytoma-related crisis, which may be fatal, has been reported following systemic corticosteroid administration. Corticosteroids should only be administered to patients with suspected or identified pheochromocytoma following consideration of individual risk / benefit.</p><p><strong>Metabolism and nutrition</strong><br />Corticosteroids, including prednisolone, can raise blood sugar levels, worsen existing diabetes and increase the risk of developing diabetes in patients on long-term corticosteroid therapy.</p><p><strong>Mental disorders</strong><br />Potentially serious mental disorders may occur during treatment with corticosteroids including prednisolone. It can be anything from euphoria, sleep disorders, mood swings, personality changes and severe depression to psychotic manifestations.<br />Existing emotional instability and psychotic tendencies can also be exacerbated by corticosteroids (see section 4.8). The symptoms typically begin within a few days or weeks after the start of treatment. Most reactions return after dose reduction or withdrawal, but specific treatment may be necessary.<br />Psychiatric effects have been reported with the withdrawal of corticosteroids, the frequency is unknown. Patients / caregivers should be encouraged to seek medical care if the patient shows mental symptoms, especially if depression or suicidal thoughts are suspected. Patients / caregivers should be aware that mental disorders may occur either during or immediately after dose reduction / discontinuation of systemic steroids.</p><p><em>Central and peripheral nervous system</em><br />Corticosteroids should be used with caution in patients with seizures.</p><p><strong>Heart</strong><br />Side effects of glucocorticoids on the cardiovascular system, for example dyslipidaemia and hypertension, can predispose in treated patients with existing cardiovascular risk factors for additional cardiovascular events at high doses and prolonged treatment times. Corticosteroids should therefore be introduced to these patients only after careful consideration, and risk-modifying measures as well as extra cardiac monitoring should be considered as needed. Low dose and treatment every other day can reduce the complications of corticosteroid treatment.</p><p><strong>Blood vessels</strong><br />Since cortisone has been reported to increase the blood clotting tendency in rare cases, thereby accelerating the development of intravascular thrombosis, thromboembolism and thrombophlebitis, corticosteroids should be used with caution in patients with thromboembolic disorders.</p><p><strong>Gastrointestinal tract</strong><br />High doses of corticosteroids can cause acute pancreatitis.<br />There are no conclusive data that states that corticosteroids cause ulcers.<br />Glucocorticoid therapy can mask peritonitis and other signs and symptoms associated with gastrointestinal conditions such as perforation, obstruction or pancreatitis. In combination with NSAIDs, the risk of gastrointestinal ulcers is increased.<br />Corticosteroids should therefore be used with caution in non-specific ulcerative colitis if there is a likelihood of imminent perforation, abscess or other pyogenic infection, diverticulitis, newly created anastomoses, or active or latent peptic ulcer.</p><p><strong>Liver and biliary tract</strong><br />Diseases of the liver and bile ducts have been reported rarely and in the majority of these cases the condition was reversible after discontinuation of treatment.<br />Appropriate monitoring measures are required.</p><p><strong>Musculoskeletal system</strong><br />Acute myopathy has been reported with high corticosteroid doses, most often in patients with neuromuscular transmission disorders (e.g., myasthenia gravis), or in patients concomitantly treated with anticholinergics, e.g. neuromuscular blocking drugs (such as pancuronium) (see section 4.5). This acute myopathy is generalised, may involve eye and respiratory muscles, and may lead to tetraparesis. Elevated creatine kinase may occur. Clinical improvement or recovery after discontinuation of corticosteroid therapy may take weeks or years.</p><p>Corticosteroids should be used with caution in patients with osteoporosis.</p><p><strong>Kidneys and urinary tract</strong><br />Corticosteroids should be used with caution in patients with renal insufficiency.</p><p><strong>Acute renal crisis (renal crisis in scleroderma)</strong><br />Caution is required in patients with systemic sclerosis as an increased incidence of (possibly fatal) renal crisis in scleroderma, with hypertension and decreased urine output, has been observed with a daily prednisolone dose of 15 mg or more.</p><p>Therefore, blood pressure and renal function (S-creatinine) should be routinely monitored. In case of suspected renal crisis, blood pressure should be kept under close control.</p><p><strong>Effects on electrolytes and fluid balance</strong><br />Systemic corticosteroids should be used with caution in patients with heart failure or hypertension. Medium and high doses of hydrocortisone or cortisone can lead to increased blood pressure, salt and water retention and increased potassium secretion.<br />These effects are less likely with synthetic derivatives, except when used in high doses. Dietary restrictions with lower salt intake and potassium supplementation may be necessary.<br />All corticosteroids increase calcium excretion.</p><p><strong>Eyes</strong><br />Visual disturbances may be reported in systemic and topical use of corticosteroids. If a patient comes with symptoms such as blurred vision or other visual disturbances, consideration should be given to referring the patient to ophthalmologist for investigation of possible causes. These may include cataracts, glaucoma or rare diseases such as central serous chorioretinopathy (CSCR), which have been reported following the use of systemic and topical corticosteroids.<strong>&nbsp;</strong></p><p><strong>Tumour lysis syndrome (TLS)</strong><br />Tumour lysis syndrome (TLS) has been reported post-marketing in patients with malignancies, including haematological malignancies and solid tumours, following the use of systemic corticosteroids alone or in combination with other cytotoxic agents. Patients at high risk for TLS, such as patients with tumours that have a high rate of cell division, high tumour burden, and high sensitivity to cytotoxic agents, should be closely monitored and appropriate precautions taken.</p><p><strong>Use in children</strong><br />Corticosteroids cause growth inhibition in infants, children and adolescents, therefore avoid long-term treatment with pharmacological doses. If long-term treatment is required, the infant / child&#39;s growth and development should be closely monitored (see section 4.2). Infants and children who are on long-term corticosteroid therapy are at particular risk of developing elevated intracranial pressure.</p><p><strong>Predo contains lactose</strong><br />Predo contains lactose. Each tablet of Predo 25 mg Tablets contains 122.5 mg lactose. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The following combinations with Predo may require dose adjustment.</p><p><strong>Phenobarbital, phenytoin, carbamazepine:</strong><br />Phenobarbital (which is also the metabolite of primidone), phenytoin and carbamazepine alone and in combination, induces the metabolism of hydrocortisone, prednisolone and methylprednisolone (shown in children with asthma) with increased dose requirements as a result. The interaction probably applies to the whole group of glucocorticoids.</p><p><strong>Non-steroidal anti-inflammatory drugs:</strong></p><ol><li>The incidence of gastrointestinal bleeding and ulceration may increase if corticosteroids are given with NSAIDs.</li><li>Corticosteroids may increase the clearance of high doses of acetylsalicylic acid, which may lead to lower salicylate levels in the serum. Salicylate levels in serum may increase upon discontinuation of corticosteroid therapy, which could lead to an increased risk of toxic effects of salicylate.</li></ol><p><strong>Diabetes drugs:</strong><br />Glucocorticoids increase blood sugar levels. Patients with diabetes mellitus receiving concomitant insulin and / or oral hypoglycaemic agents may need to adjust the dose of such treatment.</p><p><strong>Oestrogens (also oral contraceptives containing oestrogens):</strong><br />Oestrogens increase the concentration of transcortin. The effect of glucocorticoids that bind to transcortin can be enhanced and dose adjustments may be needed if oestrogens are added or removed from a stable treatment regimen.</p><p><strong>Potassium Reducing Agents:</strong><br />Potassium-reducing diuretics (e.g., thiazides, furosemide, ethacrynic acid) and other drugs that reduce the amount of potassium such as amphotericin B, xanthines and beta2-agonists, may potentiate the potassium-lowering effect of glucocorticoids.<br />Serum potassium should be closely monitored in patients receiving glucocorticoids and potassium reducing agents.</p><p><strong>Rifampicin:</strong><br />Rifampicin induces the microsomal oxidation of glucocorticoids (hydrocortisone, prednisolone, methylprednisolone). This leads to an increased steroid need during rifampicin treatment and reduced steroid need after such treatment.</p><p><strong>Isoniazid:</strong><br />Prednisolone also has a potential effect which results in increased acetylation rate and clearance of isoniazid.</p><p><strong>Oral anticoagulants:</strong><br />There are reports of altered effects of anticoagulants given concurrently with prednisolone. Prothrombin time (INR) should be monitored during treatment.</p><p><strong>CYP3A inhibitors, including medicinal products containing cobicistat:</strong><br />These are expected to increase the risk of systemic side effects. The combination should be avoided unless the benefit outweighs the increased risk of systemic side effects of corticosteroids, and if so, patients should be monitored for systemic adverse events of corticosteroids.</p><p><strong>Anticholinergic, neuromuscular blockers:</strong><br />Corticosteroids may affect the effect of anticholinergics.</p><ol><li>Acute myopathy has been reported with concomitant use of high doses of corticosteroids and anticholinergics such as neuromuscular blockers (see section 4.4).</li><li>Antagonism with the neuromuscular blocking effect of pancuronium and vecuronium has been reported in patients taking glucocorticosteroids. This interaction can be expected with all competitive neuromuscular blockers.</li></ol><p><strong>Anticholinesterases:</strong><br />Interaction between glucocorticoids and anticholinesterases such as ambenonium, neostigmine and pyridostigmine may lead to significant potency in myasthenia gravis.</p><p>If possible, treatment with anticholinesterase should be discontinued at least 24 hours before administration of glucocorticoid.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Fertility</strong><br />Animal studies have shown that corticosteroids impair fertility (see section 5.3).<strong>&nbsp;</strong></p><p><strong>Pregnancy</strong><br />In animal studies, corticosteroids have been shown to give rise to various types of malformations (palate gap, skeletal malformations, see section 5.3).</p><p>The relevance in humans is unknown.</p><p>After long-term treatment, reduced placental and birth weight have been observed in humans and animals.</p><p>In addition, there is a risk of adrenal cortex failure in the newborn during long-term treatment. Therefore, during pregnancy, corticosteroids should be given after special consideration.</p><p><strong>Breast-feeding</strong><br />Prednisolone passes into breast milk, but the risk of affecting the baby seems unlikely with therapeutic doses.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The effect of corticosteroids on the ability to drive and use machines has not been systematically investigated.</p><p>Side effects such as dizziness, visual disturbances and fatigue are possible after treatment with corticosteroids. In such adverse reactions, patients should not drive or use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Apart from substitution therapy, corticosteroid treatment always involves an overdose compared to the physiological state. Side effects mainly occur with long-term treatment, but also depend on dose size and individual sensitivity.</p><p>The following side effects have been observed and reported during treatment with prednisolone at the following frequencies: Very common (&ge;1/10), common (&ge;1/100 to &lt;1/10), uncommon (&ge;1/1,000 to &lt;1/100), rare (&ge;1/10,000 to &lt;1/1000), very rare (&lt;1/10,000), not known (cannot be estimated from the available data).</p><table border="1" cellspacing="0" cellpadding="0" style="width:1237px"><tbody><tr><td><p><strong>Organ system </strong></p></td><td><p><strong>Common</strong></p><p><strong>&nbsp;</strong></p></td><td style="width:151px"><p><strong>Uncommon</strong></p><p><strong>&nbsp;</strong></p></td><td style="width:201px"><p><strong>Rare</strong></p><p><strong>&nbsp;</strong></p></td><td style="width:387px"><p><strong>Not known&nbsp; </strong></p></td></tr><tr><td><p>Infections and infestations</p></td><td><p>Opportunistic infection<br />Activation of infection (e.g., tuberculosis)</p></td><td style="width:151px"><p>&nbsp;</p></td><td style="width:201px"><p>&nbsp;</p></td><td style="width:387px"><p>&nbsp;</p></td></tr><tr><td><p>Blood and lymphatic system</p></td><td><p>&nbsp;</p></td><td style="width:151px"><p>&nbsp;</p></td><td style="width:201px"><p>&nbsp;</p></td><td style="width:387px"><p>Leukocytosis (due to redistribution of intravascular granulocytes)</p></td></tr><tr><td><p>Immune system disorders</p></td><td><p>&nbsp;</p></td><td style="width:151px"><p>&nbsp;</p></td><td style="width:201px"><p>&nbsp;</p></td><td style="width:387px"><p>Drug hypersensitivity Anaphylactic reaction Anaphylactoid reaction</p></td></tr><tr><td><p>Endocrine disorders</p></td><td><p>Inhibition of the hypothalamic-pituitary-adrenal (HPA) axis, Cushing-like symptoms.<br />Growth retardation (in children)&nbsp;</p></td><td style="width:151px"><p>&nbsp;</p></td><td style="width:201px"><p>&nbsp;</p></td><td style="width:387px"><p>Steroid withdrawal syndrome (see section 4.4)<br />Pheochromocytoma-related crisis (see section 4.4)</p></td></tr><tr><td><p>Metabolism and nutrition disorders</p></td><td><p>Hypokalaemia&nbsp;<br />Sodium retention Increased gluconeogenesis Catabolic effects<br />Osteoporosis</p></td><td style="width:151px"><p>&nbsp;</p></td><td style="width:201px"><p>&nbsp;</p></td><td style="width:387px"><p>Metabolic acidosis&nbsp;<br />Fluid retention&nbsp;<br />Hypokalaemic alkalosis<br />Dyslipidaemia<br />Reduced glucose tolerance (diabetes mellitus may deteriorate and latent diabetes become manifest)<br />Lipomatosis&nbsp;<br />Increased appetite (which can lead to weight gain)</p></td></tr><tr><td><p>Psychiatric disorders</p></td><td><p>&nbsp;</p></td><td style="width:151px"><p>Activation of previous mental disorders (high dose)</p></td><td style="width:201px"><p>Depression, mania in patients without previously known mental illness</p></td><td style="width:387px"><p>Affective disorder (includes euphoria, affective lability, drug-related, suicidal&nbsp;&nbsp; condition)&nbsp;<br />Psychotic disorder (includes delusions, hallucinations&nbsp;&nbsp; and schizophrenia)&nbsp;<br />Mental illness&nbsp;<br />Personality change<br />Confusion state&nbsp;<br />Anxiety&nbsp;<br />Mood swings&nbsp;<br />Abnormal behaviour&nbsp;<br />Insomnia&nbsp;<br />Irritability</p></td></tr><tr><td><p>Nervous system disorders</p></td><td><p>&nbsp;</p></td><td style="width:151px"><p>&nbsp;</p></td><td style="width:201px"><p>Benign<br />intracranial hypertension</p></td><td style="width:387px"><p>Epidural lipomatosis&nbsp;<br />Seizure<br />Amnesia<br />Cognitive disorder<br />Dizziness<br />Headache</p></td></tr><tr><td><p>Eye disorders</p></td><td><p>&nbsp;</p></td><td style="width:151px"><p>Cataract&nbsp;<br />Glaucoma</p></td><td style="width:201px"><p>&nbsp;</p></td><td style="width:387px"><p>Central serous chorioretinopathy (see section 4.4)<br />Exophthalmos<br />Blurred vision (see section 4.4)</p></td></tr><tr><td><p>Cardiac disorders</p></td><td><p>&nbsp;</p></td><td style="width:151px"><p>&nbsp;</p></td><td style="width:201px"><p>&nbsp;</p></td><td style="width:387px"><p>Heart failure (in sensitive patients)<br />Bradycardia**</p></td></tr><tr><td><p>Vascular disorders</p></td><td><p>Oedema<br />hypertension</p></td><td style="width:151px"><p>&nbsp;</p></td><td style="width:201px"><p>&nbsp;</p></td><td style="width:387px"><p>Thromboembolic events</p></td></tr><tr><td><p>Respiratory, thoracic and mediastinal disorders</p></td><td><p>&nbsp;</p></td><td style="width:151px"><p>&nbsp;</p></td><td style="width:201px"><p>&nbsp;</p></td><td style="width:387px"><p>Hiccup</p></td></tr><tr><td><p>Gastrointestinal disorders</p></td><td><p>&nbsp;</p></td><td style="width:151px"><p>&nbsp;</p></td><td style="width:201px"><p>&nbsp;</p></td><td style="width:387px"><p>Peptic wound (possibly with perforation and bleeding)<br />Intestinal perforation pancreatitis<br />Ulcerative esophagitis abdominal distension Abdominal pain<br />Diarrhoea&nbsp;<br />Dyspepsia&nbsp;<br />Nausea</p></td></tr><tr><td><p>Skin and subcutaneous tissue disorders</p></td><td><p>Skin atrophy<br />Impaired wound healing</p></td><td style="width:151px"><p>&nbsp;</p></td><td style="width:201px"><p>&nbsp;</p></td><td style="width:387px"><p>Angioedema&nbsp;<br />Hirsutism&nbsp;<br />Petechiae&nbsp;<br />Ecchymosis<br />Erythema hyperhidrosis<br />Stretch marks&nbsp;<br />Itching<br />Urticaria<br />Acne</p></td></tr><tr><td><p>Musculoskeletal and connective tissue disorders</p></td><td><p>Muscular Atrophy</p></td><td style="width:151px"><p>&nbsp;</p></td><td style="width:201px"><p>Aseptic bone necrosis&nbsp;</p><p>Tendon rupture</p></td><td style="width:387px"><p>Muscle weakness<br />Myalgia&nbsp;<br />Myopathy<br />Pathological fracture<br />Neuropathic arthropathy<br />Arthralgia</p></td></tr><tr><td><p>Renal and urinary disorders</p></td><td><p>&nbsp;</p></td><td style="width:151px"><p>&nbsp;</p></td><td style="width:201px"><p>&nbsp;</p></td><td style="width:387px"><p>Acute renal crisis (renal crisis in scleroderma) *</p></td></tr><tr><td><p>Reproductive system and breast disorders</p></td><td><p>&nbsp;</p></td><td style="width:151px"><p>&nbsp;</p></td><td style="width:201px"><p>&nbsp;</p></td><td style="width:387px"><p>Irregular menstruation</p></td></tr><tr><td><p>General disorders and administration site conditions</p></td><td><p>&nbsp;</p></td><td style="width:151px"><p>&nbsp;</p></td><td style="width:201px"><p>&nbsp;</p></td><td style="width:387px"><p>Fatigue<br />Malaise</p></td></tr><tr><td><p>Investigations</p></td><td><p>&nbsp;</p></td><td style="width:151px"><p>&nbsp;</p></td><td style="width:201px"><p>&nbsp;</p></td><td style="width:387px"><p>Increased calcium levels in the urine Elevated alanine aminotransferase Elevated aspartate aminotransferase Increased blood alkaline phosphatase<br />Elevated blood urea<br />Suppression of skin test reactions<sup>1</sup></p></td></tr></tbody></table><p><sup>1</sup>Not MedDRA term.&nbsp;<br />* Acute renal crisis (scleroderma renal crisis)&nbsp;<br />The incidence of acute renal crisis varies between the different subpopulations. The greatest risk has been reported in patients with diffuse systemic sclerosis. The minimum risk has been reported in patients with limited systemic sclerosis (2%) and systemic sclerosis with juvenile onset (1%).&nbsp;<br />** Following high doses.</p><p><strong>Reporting of suspected adverse reactions</strong><br />Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:</p><ul><li>Saudi Arabia</li></ul><p>The National Pharmacovigilance Centre (NPC)</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa&nbsp;&nbsp;&nbsp;</p><ul><li>Other GCC States</li></ul><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Reports of acute toxicity and / or death following glucocorticoid overdose are rare.</p><p>Possibly, acute overdose may aggravate preexisting disease states such as ulcers, electrolyte disorders, infections and oedema.</p><p><strong>Treatment:</strong> Not usually required. If proper gastric emptying, with charcoal.<br />In case of overdose, there is no specific antidote, but the treatment is supportive and symptomatic.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Glucocorticoid</p><p>ATC code: H02AB06</p><p>Synthetic glucocorticoid with anti-inflammatory, immunosuppressive and antiallergic action.</p><p>Prednisolone has, by weight, 4-5 times higher anti-inflammatory effect than cortisone, but affects electrolyte turnover to a lesser extent.</p><p>The mechanism of action is not yet fully understood.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Absorption</strong><br />Prednisolone is rapidly absorbed into the gastrointestinal tract when given orally. Maximum plasma concentration is achieved after 1 to 2 hours after oral administration. The plasma half-life is normally 2 to 4 hours. Its initial absorption, but not total bioavailability, is affected by food.</p><p><strong>Distribution</strong><br />Prednisolone is highly bound to plasma proteins and has high affinity for the transcortin.</p><p>The volume of distribution and clearance are reported to increase with transition from low to medium doses.</p><p><strong>Metabolism</strong><br />Prednisolone is metabolised primarily in the liver to a biologically inactive compound.</p><p>Prednisolone can be reversibly converted to prednisone by 11&beta;-hydroxysteroid dehydrogenase.</p><p>The absolute bioavailability of prednisolone is on average 82% compared to intravenously administered prednisolone following a single 10 mg dose. At normal dosing, the effective duration is calculated to be 12-36 hours.</p><p><strong>Elimination</strong><br />Prednisolone is excreted via the urine as free and conjugated metabolites, along with small amounts of unchanged prednisolone.</p><p>More than 90% of the given amount is excreted in the urine. 7-15% is excreted in unchanged form.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In animal experiments, corticosteroids have been shown to give rise to various types of malformations (palate gap, skeletal malformations). After long-term treatment, reduced placental and birth weight have been observed in animals.</p><p>Corticosteroids have been shown to reduce fertility when administered to the rat.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Lactose</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pregelatinized starch</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Maize starch</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Microcrystalline cellulose</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Povidone</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Magnesium stearate</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>None known</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                36 months.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C.</p><p>Store in the original package in order to protect from light.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Clear PVC/PVDC-aluminum blisters.</p><p>Pack size: 30 Tablets (3 blisters; each blister contains 10 tablets).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not available.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Jazeera Pharmaceutical Industries

Al-Kharj Road

P.O. BOX 106229

Riyadh 11666, Saudi Arabia

Tel: + (966-11) 8107023, + (966-11) 2142472

Fax: + (966-11) 2078170

e-mail: SAPV@hikma.com
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                27 March 2024
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>